Organogenesis Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Umsatz von Organogenesis Holdings wird voraussichtlich um 8.4% pro Jahr zurückgehen, während der Jahresgewinn um 19.8% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 20.9% pro Jahr steigen.
Wichtige Informationen
19.8%
Wachstumsrate der Gewinne
20.86%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.3% |
| Wachstumsrate der Einnahmen | -8.4% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 08 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • Apr 07
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight
Summary Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant results in a randomized controlled trial for diabetic foot ulcers, strengthening ORGO’s clinical and commercial position. ORGO faces a 25–38% revenue decline in 2026 from CMS reimbursement changes, but RCT-backed evidence de-risks coverage and supports a recovery thesis into 2027. With ORGO's EV/sales at 0.7x and EV/EBITDA at 5.4x trailing, the market is discounting severe but temporary revenue pressure, offering clear re-rating upside if reimbursement stabilizes. Read the full article on Seeking Alpha
Narrativ-Update • Feb 19
ORGO: FDA Rolling BLA For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have maintained their $8.00 price target on Organogenesis Holdings, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Organogenesis completed a planned Type B meeting with the FDA, securing confirmation to begin a rolling Biologics License Application for ReNu, with the filing expected to start before the end of December (Key Developments).Narrativ-Update • Feb 05
ORGO: FDA BLA Progress For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have slightly trimmed their price targets on Organogenesis Holdings, citing updated assumptions that include a modestly higher discount rate, slightly stronger revenue growth and profit margin estimates, and a somewhat lower future P/E multiple. What's in the News Organogenesis Holdings reported a successful Type B meeting with the FDA that cleared the way to start a rolling Biologics License Application, or BLA, for its ReNu product, with filing planned before the end of December (Key Developments).Narrativ-Update • Jan 21
ORGO: FDA Rolling Submission For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have nudged their price target on Organogenesis Holdings higher to US$8.00, citing slightly firmer assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Completed a planned Type B meeting with the FDA, receiving confirmation to initiate a rolling Biologics License Application for ReNu, targeted before the end of December (Key Developments).Analyseartikel • Jan 17
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders won't be pleased to see that the share price has had a very...Analyseartikel • Jan 11
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Narrativ-Update • Jan 06
ORGO: Regulatory Momentum For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have raised their fair value estimate for Organogenesis Holdings from US$7.00 to US$8.00, citing changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E estimates as key drivers of the updated price target. What's in the News Completed a planned Type-B meeting with the FDA, with confirmation to begin a rolling Biologics License Application (BLA) for ReNu before the end of December (Key Developments).
Narrativ-Update • Dec 18
ORGO: Upcoming Knee Osteoarthritis BLA Filing Will Drive Long Term Upside
Analysts have modestly lifted their price target on Organogenesis Holdings to 8.50 dollars from 8.50 dollars, reflecting slightly higher long term profitability and valuation assumptions despite essentially unchanged growth and fair value estimates. What's in the News Completed a planned Type B FDA meeting confirming the path to initiate a rolling Biologics License Application for ReNu for knee osteoarthritis before the end of December, which advances the regulatory strategy for this lead asset (Key Developments) Raised 2025 guidance and projected net product revenue between 500.0 million dollars and 525.0 million dollars, an increase of 4% to 9% year over year, with expected net income between 8.6 million dollars and 25.4 million dollars (Key Developments) Reported that the second Phase 3 randomized controlled trial of ReNu in knee osteoarthritis did not meet its primary endpoint for statistical significance, but showed numerical pain reduction improvements and maintained a favorable safety profile, supporting plans for an FDA BLA filing (Key Developments) Highlighted that ReNu has been evaluated in three large randomized controlled trials involving more than 1,300 patients and previously received FDA Regenerative Medicine Advanced Therapy designation for knee osteoarthritis, which reinforces its clinical and regulatory foundation (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at 8.50 dollars per share, indicating a stable view of intrinsic equity value.Narrativ-Update • Dec 04
ORGO: Upcoming Knee Osteoarthritis FDA Filing Will Support Future Share Price Expansion
Analysts have modestly raised their price target on Organogenesis Holdings to 8.50 dollars from 7.50 dollars, citing a slightly higher assumed future price to earnings multiple that more than offsets minor adjustments to the discount rate and margin assumptions. What's in the News Raised 2025 earnings guidance, expecting net product revenue of 500 million to 525 million dollars, up 4% to 9% year over year from 482 million dollars in 2024, with projected net income between 8.6 million and 25.4 million dollars (company guidance).Analyseartikel • Nov 27
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Shares Bounce 27% But Its Business Still Trails The Industry
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have had a really impressive month, gaining 27% after a shaky period...Narrativ-Update • Nov 20
ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion
Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.Narrativ-Update • Aug 15
CMS Reform And Capacity Expansion Will Unlock Long Term Value
With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.Analyseartikel • May 04
Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have been powering on, with a gain of...
Neues Narrativ • Apr 25
LCD Delays And ReNu Progress Will Unlock Market Potential
Delay in LCDs implementation offers a chance to capitalize on demand, boosting near-term revenue and market share for key products.Analyseartikel • Mar 02
There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise
The Organogenesis Holdings Inc. ( NASDAQ:ORGO ) share price has done very well over the last month, posting an...Seeking Alpha • Oct 15
Organogenesis: Lurking Disruption With Recovery To Follow
Summary Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity is adequate and excellent potential for acquisition on expected pullbacks. Read the full article on Seeking AlphaAnalyseartikel • Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong...Analyseartikel • Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights Organogenesis Holdings to hold its Annual General Meeting on 20th of June Salary of US$908.7k is part of...Seeking Alpha • Jun 10
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Summary Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues. The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues. In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu. Read the full article on Seeking AlphaAnalyseartikel • May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) recent soft profit numbers didn't appear to worry shareholders, as the...Analyseartikel • May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analyseartikel • Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 381 | -19 | N/A | N/A | 1 |
| 12/31/2027 | 344 | -37 | N/A | N/A | 1 |
| 12/31/2026 | 282 | -114 | N/A | N/A | 1 |
| 3/31/2026 | 515 | -15 | 17 | 31 | N/A |
| 12/31/2025 | 564 | 20 | -24 | -10 | N/A |
| 9/30/2025 | 465 | -9 | -52 | -39 | N/A |
| 6/30/2025 | 430 | -11 | -46 | -33 | N/A |
| 3/31/2025 | 459 | -20 | -7 | 4 | N/A |
| 12/31/2024 | 482 | -1 | 4 | 14 | N/A |
| 9/30/2024 | 455 | -7 | 4 | 14 | N/A |
| 6/30/2024 | 448 | -17 | 9 | 22 | N/A |
| 3/31/2024 | 435 | 6 | 7 | 26 | N/A |
| 12/31/2023 | 433 | 5 | 7 | 31 | N/A |
| 9/30/2023 | 449 | 13 | -4 | 28 | N/A |
| 6/30/2023 | 457 | 10 | -19 | 17 | N/A |
| 3/31/2023 | 461 | 13 | -16 | 18 | N/A |
| 12/31/2022 | 451 | 16 | -9 | 25 | N/A |
| 9/30/2022 | 463 | 59 | 7 | 35 | N/A |
| 6/30/2022 | 460 | 71 | 23 | 57 | N/A |
| 3/31/2022 | 462 | 83 | 32 | 65 | N/A |
| 12/31/2021 | 467 | 94 | 31 | 62 | N/A |
| 9/30/2021 | 446 | 62 | 36 | 67 | N/A |
| 6/30/2021 | 433 | 69 | 28 | 48 | N/A |
| 3/31/2021 | 379 | 43 | 3 | 21 | N/A |
| 12/31/2020 | 338 | 17 | -12 | 5 | N/A |
| 9/30/2020 | 306 | -5 | -40 | -24 | N/A |
| 6/30/2020 | 270 | -37 | -50 | -38 | N/A |
| 3/31/2020 | 266 | -42 | -51 | -41 | N/A |
| 12/31/2019 | 261 | -39 | N/A | -34 | N/A |
| 9/30/2019 | 250 | -46 | N/A | -45 | N/A |
| 6/30/2019 | 236 | -48 | N/A | -62 | N/A |
| 3/31/2019 | 215 | -58 | N/A | -66 | N/A |
| 12/31/2018 | 193 | -65 | N/A | -61 | N/A |
| 9/30/2018 | 183 | -60 | N/A | -46 | N/A |
| 6/30/2018 | 184 | -52 | N/A | -25 | N/A |
| 3/31/2018 | 187 | -32 | N/A | -9 | N/A |
| 12/31/2017 | 199 | -9 | N/A | -3 | N/A |
| 12/31/2016 | 139 | -17 | N/A | -5 | N/A |
| 12/31/2015 | 99 | -24 | N/A | -10 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ORGO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ORGO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ORGO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ORGODie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-8.4% pro Jahr).
Hohe Wachstumseinnahmen: ORGODie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-8.4% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ORGO in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 12:40 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Organogenesis Holdings Inc. wird von 7 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Gorman | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Richard Newitter | Leerink Partners LLC |